• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医生和管理人员报告的医生执业机构药物使用管理成本:一项横断面调查。

The Physician and Administrator-Reported Cost of Drug Utilization Management to Physician Practices: A Cross-Sectional Survey.

作者信息

Edwards Marie Louise, Yin Perry T, Kuehn Michael, Bratti Keith, Kirson Noam, Jena Anupam, Howell Scott

机构信息

Analysis Group, Inc., New York, NY, USA.

Market Access Innovation, US Pharmaceuticals, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

出版信息

Pharmacoecon Open. 2022 Sep;6(5):711-721. doi: 10.1007/s41669-022-00351-5. Epub 2022 Jul 23.

DOI:10.1007/s41669-022-00351-5
PMID:35871127
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9308474/
Abstract

BACKGROUND

The use of drug utilization management techniques such as formulary exclusions, prior authorizations, and step edits has risen sharply during the last decade, contributing to growing administrative costs for physician practices. However, limited data exist on the extent of these administrative costs, with previous studies relying on data from over a decade ago.

OBJECTIVE

The aim of this study was to assess physician and practice administrator experiences with drug utilization management.

METHODS

A national survey was conducted between 9 February and 30 March 2021, targeting 925 physicians and administrators working at medical practices in the US. Time spent by physicians and their staff on tasks related to drug utilization management for prescription medications was collected and used to calculate the dollar value of that time.

RESULTS

We estimated that physicians spent a median of 4.0 h per week on drug utilization management, while nurses spent 15.0 h and other staff spent between 3.6 and 10.0 h on drug utilization management per physician per week. This time was associated with a calculated median dollar value of $75,927 per physician per year. Extrapolating this estimate to a national scale suggests that time spent annually by physician practices on drug utilization management could be valued at more than $43 billion.

CONCLUSIONS

Drug utilization management results in significant time spent by US physician practices, which in turn, results in meaningful costs to these practices. As the prevalence of drug utilization management continues to grow, the impact on physician practices will remain an important topic.

摘要

背景

在过去十年中,诸如药品目录排除、预先授权和阶梯编辑等药物利用管理技术的使用急剧增加,导致医生诊所的行政成本不断上升。然而,关于这些行政成本的规模的数据有限,以前的研究依赖于十多年前的数据。

目的

本研究的目的是评估医生和诊所管理人员在药物利用管理方面的经验。

方法

2021年2月9日至3月30日进行了一项全国性调查,目标是美国医疗诊所工作的925名医生和管理人员。收集了医生及其工作人员花在与处方药药物利用管理相关任务上的时间,并用于计算这段时间的货币价值。

结果

我们估计,医生每周花在药物利用管理上的时间中位数为4.0小时,而护士为15.0小时,其他工作人员每位医生每周花在药物利用管理上的时间在3.6至10.0小时之间。这段时间计算得出的每位医生每年的货币价值中位数为75,927美元。将这一估计推算到全国范围表明,医生诊所每年花在药物利用管理上的时间价值可能超过430亿美元。

结论

药物利用管理导致美国医生诊所花费大量时间,进而给这些诊所带来可观的成本。随着药物利用管理的普及持续增加,对医生诊所的影响仍将是一个重要话题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a26f/9440166/0c9cccba2183/41669_2022_351_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a26f/9440166/0c9cccba2183/41669_2022_351_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a26f/9440166/0c9cccba2183/41669_2022_351_Fig1_HTML.jpg

相似文献

1
The Physician and Administrator-Reported Cost of Drug Utilization Management to Physician Practices: A Cross-Sectional Survey.医生和管理人员报告的医生执业机构药物使用管理成本:一项横断面调查。
Pharmacoecon Open. 2022 Sep;6(5):711-721. doi: 10.1007/s41669-022-00351-5. Epub 2022 Jul 23.
2
Physician perceptions of drug utilization management: Results of a national survey.医生对药物利用管理的看法:全国性调查结果。
PLoS One. 2022 Sep 20;17(9):e0274772. doi: 10.1371/journal.pone.0274772. eCollection 2022.
3
US physician practices versus Canadians: spending nearly four times as much money interacting with payers.美国医生与加拿大医生的做法对比:与支付方互动的花费几乎是后者的四倍。
Health Aff (Millwood). 2011 Aug;30(8):1443-50. doi: 10.1377/hlthaff.2010.0893. Epub 2011 Aug 3.
4
Quantifying The Economic Burden Of Drug Utilization Management On Payers, Manufacturers, Physicians, And Patients.量化药物利用管理对支付方、制造商、医生和患者的经济负担。
Health Aff (Millwood). 2021 Aug;40(8):1206-1214. doi: 10.1377/hlthaff.2021.00036.
5
Assessment of Satisfaction With the Electronic Health Record Among Physicians in Physician-Owned vs Non-Physician-Owned Practices.评估医生对电子病历的满意度:在医生所有与非医生所有的医疗机构中。
JAMA Netw Open. 2022 Apr 1;5(4):e228301. doi: 10.1001/jamanetworkopen.2022.8301.
6
What are the costs to physicians of administrative complexity in their interactions with payers?医生与支付方互动中行政复杂性给医生带来的成本有哪些?
Find Brief. 2010 Mar;13(2):1-3.
7
The Growing Executive-Physician Wage Gap in Major US Nonprofit Hospitals and Burden of Nonclinical Workers on the US Healthcare System.美国主要非营利性医院中高管医生薪酬差距不断扩大以及非临床工作人员给美国医疗体系带来的负担。
Clin Orthop Relat Res. 2018 Oct;476(10):1910-1919. doi: 10.1097/CORR.0000000000000394.
8
Compared to Canadians, U.S. physicians spend nearly four times as much money interacting with payers.与加拿大人相比,美国医生与付款人互动所花费的资金几乎是加拿大人的四倍。
Find Brief. 2011 Nov;14(8):1-3.
9
Identifying desired qualifications, tasks, and organizational characteristics of practice managers-a cross-sectional survey among group practice physicians in Germany.确定执业经理人的期望资质、任务和组织特征——德国团体执业医师的横断面调查。
BMC Health Serv Res. 2022 Jun 24;22(1):821. doi: 10.1186/s12913-022-08199-5.
10
What does it cost physician practices to interact with health insurance plans?医生的执业机构与医疗保险计划互动需要花费多少成本?
Health Aff (Millwood). 2009 Jul-Aug;28(4):w533-43. doi: 10.1377/hlthaff.28.4.w533. Epub 2009 May 14.

引用本文的文献

1
National perspectives of barriers by insurance and pharmacy benefit managers in pediatric inflammatory bowel disease.保险和药品福利管理人员对儿童炎症性肠病治疗障碍的全国性观点。
JPGN Rep. 2025 Feb 10;6(2):80-90. doi: 10.1002/jpr3.70004. eCollection 2025 May.
2
Gold Carding Policies: Reducing the Barriers Between Payers and Providers.金卡政策:减少支付方与医疗服务提供方之间的障碍。
Neurol Clin Pract. 2024 Apr;14(2):e200256. doi: 10.1212/CPJ.0000000000200256. Epub 2024 Jan 10.
3
Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.

本文引用的文献

1
Impact of a pharmacist-run refill and prior authorization program on physician workload.药剂师管理的药品续配和事先授权计划对医生工作量的影响。
J Am Pharm Assoc (2003). 2022 May-Jun;62(3):727-733.e1. doi: 10.1016/j.japh.2021.12.002. Epub 2021 Dec 7.
2
Quantifying The Economic Burden Of Drug Utilization Management On Payers, Manufacturers, Physicians, And Patients.量化药物利用管理对支付方、制造商、医生和患者的经济负担。
Health Aff (Millwood). 2021 Aug;40(8):1206-1214. doi: 10.1377/hlthaff.2021.00036.
3
Cornerstones of 'fair' drug coverage: appropriate cost sharing and utilization management policies for pharmaceuticals.
使用奥瑞珠单抗进行一线治疗与二线或后续治疗的多发性硬化症患者的真实世界临床和经济结果
Neurol Ther. 2023 Oct;12(5):1709-1728. doi: 10.1007/s40120-023-00523-3. Epub 2023 Jul 17.
药品公平覆盖的基石:适当的药品费用分担和利用管理政策。
J Comp Eff Res. 2021 May;10(7):537-547. doi: 10.2217/cer-2021-0027. Epub 2021 Mar 1.
4
Stakeholders find that step therapy should be evidence-based, flexible, and transparent: assessing appropriateness using a consensus approach.利益相关者认为,阶梯式疗法应该基于证据、灵活且透明:采用共识方法评估其适宜性。
J Manag Care Spec Pharm. 2021 Feb;27(2):268-275. doi: 10.18553/jmcp.2021.27.2.268.
5
Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries.医保受益人与丁丙诺啡-纳洛酮处方和医院及急诊使用相关的处方优先审批政策的关联。
JAMA Netw Open. 2020 Apr 1;3(4):e203132. doi: 10.1001/jamanetworkopen.2020.3132.
6
Refocusing Medication Prior Authorization on Its Intended Purpose.将药物预先授权重新聚焦于其预期目的。
JAMA. 2020 Feb 25;323(8):703-704. doi: 10.1001/jama.2019.21428.
7
Health Care Administrative Costs in the United States and Canada, 2017.2017 年美国和加拿大的医疗保健管理成本。
Ann Intern Med. 2020 Jan 21;172(2):134-142. doi: 10.7326/M19-2818. Epub 2020 Jan 7.
8
Physician Perceptions of Step Therapy Prescribing Requirements.医生对阶梯式治疗规定的看法。
J Manag Care Spec Pharm. 2019 Nov;25(11):1210-1224. doi: 10.18553/jmcp.2019.25.11.1210.
9
Waste in the US Health Care System: Estimated Costs and Potential for Savings.美国医疗体系中的浪费:估计成本和节约潜力。
JAMA. 2019 Oct 15;322(15):1501-1509. doi: 10.1001/jama.2019.13978.
10
Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis.计划层面的准入限制对类风湿性关节炎或银屑病关节炎患者生物制剂疗效的影响
Pharmacoecon Open. 2020 Mar;4(1):105-117. doi: 10.1007/s41669-019-0152-1.